ArticleRevista peruana de medicina experimental y salud publica2025
Genomic diversity of uropathogenic Escherichia coli in clinical isolates from six latin american countries, 2018-2023.
Article in Revista peruana de medicina experimental y salud publica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Antimicrobial Resistance, Biofilm Formation, and Phylogenetic Distribution ofAntibiotics (Basel, Switzerland) · 2026Article
- Phylogenetic Groups, Virulence Factors, and Antimicrobial Susceptibility ofAntibiotics (Basel, Switzerland) · 2026Article
- Versatile and portable Cas12a-mediated detection of antibiotic resistance markers.Scientific reports · 2026Article
- Genomic insights into selected multidrug-resistant and ESBL-producing uropathogenicFrontiers in microbiology · 2026Article
- Evaluation of Virulence Profiles and Molecular Typing of ESBL-Producing UropathogenicInfection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMotivation for the study. To contribute to the genomic surveillance of UPEC in clinical samples from Latin America, in response to the growing public health problem represented by UTIs and their resistance to antimicrobials. Main findings. Our study revealed a high frequency of high-risk clones, such as ST131 and ST1193. Critical mutations were identified in genes associated with resistance to multiple antibiotics, including fluoroquinolones, beta-lactams, and fosfomycin. Implications. Our results highlight the urgent need to strengthen UPEC surveillance in Latin America. Tracking resistant strains and implementing measures to limit their spread is crucial and has a significant impact on the effectiveness of available treatments. OBJECTIVE.: To genetically characterize clinical isolates of uropathogenic Escherichia coli (UPEC) from hospitals in Peru and contextualize them against 127 additional UPEC genomes reported in six Latin American countries between 2018 and 2023. MATERIALS AND METHODS.: The genomes of 16 Peruvian UPEC isolates were sequenced, assembled and supplemented with 127 genomes available in the NCBI public database. Serotypes, sequence types (STs), antimicrobial resistance (AMR) genes, and resistance-associated mutations were identified. A phylogenetic analysis was also conducted in order to determine evolutionary relations and distribution in phylogroups. RESULTS.: The ST131 clone was the most prevalent (42.7%), followed by ST1193 (13.3%). Phylogroup B2 was widely predominant (83.2%), with serotype O25:H4 standing out. The resistance genes blaTEM-1, blaCTX-M-15, and blaCTX-M-27 were identified with high frequency, as well as mutations in gyrA and parC associated with fluoroquinolone resistance, especially in the ST131 clone. CONCLUSION.: Our findings show high circulation of high-risk UPEC clones, such as ST131 and ST1193, in Latin America, along with a notable burden of genes and mutations linked to multidrug resistance, highlighting the need to strengthen regional genomic surveillance.
backgroundMotivation for the study. To contribute to the genomic surveillance of UPEC in clinical samples from Latin America, in response to the growing public health problem represented by UTIs and their resistance to antimicrobials. Main findings. Our study revealed a high frequency of high-risk clones, such as ST131 and ST1193. Critical mutations were identified in genes associated with resistance to multiple antibiotics, including fluoroquinolones, beta-lactams, and fosfomycin. Implications. Our results highlight the urgent need to strengthen UPEC surveillance in Latin America. Tracking resistant strains and implementing measures to limit their spread is crucial and has a significant impact on the effectiveness of available treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.